



Advanced Research of Cartilage Repair and Regeneration

Guest Editor:

Prof. Dr. Zongbing You

Department of Structural &
Cellular Biology, Tulane
University, New Orleans, LA
70112, USA

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editor

Arthritis is the most common cause of disability, the most common form of which is osteoarthritis (OA). Early OA is treated with joint-preserving interventions such as lifestyle modification, pharmaceuticals, and surgery. The most commonly used surgical modalities for the treatment of localized cartilage lesions in early OA are microfracture, mosaicplasty (osteochondral autograft), and autologous chondrocyte implantation. These therapies may restore function and relieve pain for a short period, but they are not able to arrest or delay disease progression. End-stage OA is treated with joint replacement; however, the functional outcomes can be poor and the lifespan of prostheses is limited. New strategies based on mesenchymal stem cells are being actively tested in humans and animals; however, few have been successfully translated into clinical practice. This Special Issue on Advanced Research of Cartilage Repair and Regeneration invites original and review articles focusing on stem cells, scaffold, and chondrogenic factors as well as their combinations for articular cartilage regeneration and repair. In vivo animal studies with long-term follow-up are particularly welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI